Showing results (41-50 of 131) with videos related to

Sort By:
Pageof 14
Cancer Research|November 5, 2002
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavirHeleen A Bardelmeijer, Mariët Ouwehand, Tessa Buckle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Increased penetration of paclitaxel into the brain by inhibition of P-GlycoproteinE Marleen Kemper, A Erik van Zandbergen, Cindy Cleypool, et al.
Cancer Cell|October 16, 2007
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for gliomaSophia W M Bruggeman, Danielle Hulsman, Ellen Tanger, et al.
Cell Reports|July 7, 2017
Identification of a Druggable Pathway Controlling Glioblastoma InvasivenessNora Pencheva, Mark C de Gooijer, Daniel J Vis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2013
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analoguesFan Lin, Serena Marchetti, Dick Pluim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposideJurjen S Lagas, Lin Fan, Els Wagenaar, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 14, 2011
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexateMaria L H Vlaming, Anita van Esch, Evita van de Steeg, et al.
Molecular Cancer Therapeutics|December 10, 2009
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivoMaria L H Vlaming, Anita van Esch, Zeliha Pala, et al.
Pharmacological Research|May 10, 2026
Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glueAlfred Schinkel, Davinia Arguedas, Viët Bui, et al.
FEBS Open Bio|November 13, 2023
Acquired and intrinsic resistance to vemurafenib in BRAFV600E -driven melanoma brain metastasesPing Zhang, Laura Esmee Kuil, Levi Conrad Maria Buil, et al.
Pageof 14